- Home
- DSM vs AQST Comparison
DSM vs AQST Comparison
Compare DSM & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | AQST |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 707.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DSM | AQST |
|---|---|---|
| Price | $6.18 | $6.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 161.7K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.69 | $2.12 |
| 52 Week High | $6.05 | $7.55 |
Technical Indicators
Market Signals| Indicator | DSM | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 71.67 | 56.27 |
| Support Level | $5.97 | $5.84 |
| Resistance Level | $6.05 | $6.06 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 96.15 | 78.98 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.